Skip to main content
Erschienen in: Breast Cancer 1/2017

01.02.2016 | Original Article

Impact of young age on local control after partial breast irradiation in Japanese patients with early stage breast cancer

verfasst von: Kazuhiko Sato, Yoshio Mizuno, Hiromi Fuchikami, Masahiro Kato, Takahiro Shimo, Jun Kubota, Naoko Takeda, Yuko Inoue, Hiroshi Seto, Tomohiko Okawa

Erschienen in: Breast Cancer | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Partial breast irradiation (PBI) is an alternative to whole breast irradiation (WBI) for breast-conserving therapy (BCT). A randomised phase 3 trial demonstrated that PBI using multicatheter brachytherapy had an equivalent rate of local recurrence, disease-free survival, and overall survival as compared to WBI. However, limited data are available on PBI efficacy for young patients with breast cancer.

Methods

We evaluated consecutive patients with Tis-2 (≤ 3 cm) N0-1 breast cancer who underwent BCT. For PBI, patients received radiotherapy using multicatheter brachytherapy in an accelerated manner with a dose of 32 Gy in eight fractions over 5–6 days. For WBI, patients received an external beam radiation therapy that was applied to the entire breast with a total dose of 50 Gy in fractions of 2 Gy for 5 weeks. Two hundred seventy-four patients with 278 lesions received PBI; 190 patients with 193 lesions received WBI.

Results

Patients aged <50 years including 98 women with 99 lesions receiving PBI and 85 women with 85 lesions receiving WBI were selected. Ipsilateral breast tumor recurrence rate was 3.0 and 2.4 % by PBI and WBI, respectively (P = 0.99). There was no significant difference in 4-year probability of disease-free survival (97.6 and 91.4 % for PBI and WBI, respectively; P = 0.87).

Conclusions

This is the first report of PBI efficacy in young patients in Asia. Although it is a nonrandomized retrospective chart review of a small cohort of patients with a relatively short follow-up period, PBI may be a better option than WBI following BCS in some young patients with breast cancer.
Literatur
2.
Zurück zum Zitat Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer. 2015;22:235–44. doi:10.1007/s12282-015-0599-6.CrossRefPubMed Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer. 2015;22:235–44. doi:10.​1007/​s12282-015-0599-6.CrossRefPubMed
4.
Zurück zum Zitat Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefPubMed Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefPubMed
5.
Zurück zum Zitat Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.CrossRefPubMed Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.CrossRefPubMed
7.
Zurück zum Zitat Tuttle TM, Jarosek S, Habermann EB, Yee D, Yuan J, Virnig BA. Omission of radiation therapy after breast-conserving surgery in the United States: a population-based analysis of clinicopathologic factors. Cancer. 2012;118:2004–13. doi:10.1002/cncr.26505.CrossRefPubMed Tuttle TM, Jarosek S, Habermann EB, Yee D, Yuan J, Virnig BA. Omission of radiation therapy after breast-conserving surgery in the United States: a population-based analysis of clinicopathologic factors. Cancer. 2012;118:2004–13. doi:10.​1002/​cncr.​26505.CrossRefPubMed
8.
Zurück zum Zitat Saji S, Hiraoka M, Tokuda Y, Fukui N, Ikeda T. Trends in local therapy application for early breast cancer patients in the Japanese Breast Cancer Society Breast Cancer Registry during 2004–2009. Breast Cancer. 2012;19:1–3. doi:10.1007/s12282-011-0308-z.CrossRefPubMed Saji S, Hiraoka M, Tokuda Y, Fukui N, Ikeda T. Trends in local therapy application for early breast cancer patients in the Japanese Breast Cancer Society Breast Cancer Registry during 2004–2009. Breast Cancer. 2012;19:1–3. doi:10.​1007/​s12282-011-0308-z.CrossRefPubMed
10.
11.
Zurück zum Zitat Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16:266–73. doi:10.1016/S1470-2045(14)71221-5.CrossRefPubMed Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16:266–73. doi:10.​1016/​S1470-2045(14)71221-5.CrossRefPubMed
12.
Zurück zum Zitat Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRefPubMed Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRefPubMed
13.
15.
Zurück zum Zitat Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2015;S0140–6736(15):00471–7. doi:10.1016/S0140-6736(15)00471-7. Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2015;S0140–6736(15):00471–7. doi:10.​1016/​S0140-6736(15)00471-7.
16.
Zurück zum Zitat Sato K, Mizuno Y, Kato M, Shimo T, Kubota J, Takeda N, et al. Intraoperative open-cavity implant for accelerated partial breast irradiation using high-dose rate multicatheter brachytherapy in Japanese breast cancer patients: a single-institution registry study. J Cancer Ther. 2012;3:822–30. doi:10.4236/jct.2012.325104.CrossRef Sato K, Mizuno Y, Kato M, Shimo T, Kubota J, Takeda N, et al. Intraoperative open-cavity implant for accelerated partial breast irradiation using high-dose rate multicatheter brachytherapy in Japanese breast cancer patients: a single-institution registry study. J Cancer Ther. 2012;3:822–30. doi:10.​4236/​jct.​2012.​325104.CrossRef
17.
Zurück zum Zitat Recht A, Silver B, Schnitt S, Connolly J, Hellman S, Harris JR. Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency and salvage. Int J Radiat Oncol Biol Phys. 1985;11:1271–6. doi:10.1016/0360-3016(85)90241-X.CrossRefPubMed Recht A, Silver B, Schnitt S, Connolly J, Hellman S, Harris JR. Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency and salvage. Int J Radiat Oncol Biol Phys. 1985;11:1271–6. doi:10.​1016/​0360-3016(85)90241-X.CrossRefPubMed
18.
Zurück zum Zitat Saika K, Sobue T. Epidemiology of breast cancer in Japan and the USA. JMAJ. 2009;52:39–44. Saika K, Sobue T. Epidemiology of breast cancer in Japan and the USA. JMAJ. 2009;52:39–44.
21.
Zurück zum Zitat Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987–1001. doi:10.1016/j.ijrobp.2009.02.031.CrossRefPubMed Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987–1001. doi:10.​1016/​j.​ijrobp.​2009.​02.​031.CrossRefPubMed
22.
Zurück zum Zitat Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010;94:264–73. doi:10.1016/j.radonc.2010.01.014.CrossRefPubMed Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010;94:264–73. doi:10.​1016/​j.​radonc.​2010.​01.​014.CrossRefPubMed
23.
Zurück zum Zitat Buchholz TA, Somerfield MR, Griggs JJ, El-Eid S, Hammond ME, Lyman GH, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol. 2014;32:1502–6. doi:10.1200/JCO.2014.55.1572.CrossRefPubMed Buchholz TA, Somerfield MR, Griggs JJ, El-Eid S, Hammond ME, Lyman GH, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol. 2014;32:1502–6. doi:10.​1200/​JCO.​2014.​55.​1572.CrossRefPubMed
25.
Zurück zum Zitat Stull TS, Catherine Goodwin M, Chernick MR, Carella RJ, Frazier TG, et al. A single-institution review of accelerated partial breast irradiation in patients considered “cautionary” by the American Society for Radiation Oncology. Ann Surg Oncol. 2012;19:553–9. doi:10.1245/s10434-011-1941-7.CrossRefPubMed Stull TS, Catherine Goodwin M, Chernick MR, Carella RJ, Frazier TG, et al. A single-institution review of accelerated partial breast irradiation in patients considered “cautionary” by the American Society for Radiation Oncology. Ann Surg Oncol. 2012;19:553–9. doi:10.​1245/​s10434-011-1941-7.CrossRefPubMed
26.
Zurück zum Zitat Sato K, Mizuno Y, Fuchikami H, Kato M, Shimo T, Kubota J, et al. Single-institution comparison of accelerated partial breast irradiation and whole breast irradiation in breast cancer patients with unfavorable parameters by the American Society for Radiation Oncology guidelines. J Tumor. 2014;2:129–33. Sato K, Mizuno Y, Fuchikami H, Kato M, Shimo T, Kubota J, et al. Single-institution comparison of accelerated partial breast irradiation and whole breast irradiation in breast cancer patients with unfavorable parameters by the American Society for Radiation Oncology guidelines. J Tumor. 2014;2:129–33.
28.
Zurück zum Zitat Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98. doi:10.1056/NEJMoa1209825.CrossRefPubMed Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98. doi:10.​1056/​NEJMoa1209825.CrossRefPubMed
29.
30.
32.
Zurück zum Zitat Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269–77. doi:10.1016/S1470-2045(13)70497-2.CrossRefPubMed Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269–77. doi:10.​1016/​S1470-2045(13)70497-2.CrossRefPubMed
33.
Zurück zum Zitat Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603–13. doi:10.1016/S0140-6736(13)61950-9.CrossRefPubMed Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603–13. doi:10.​1016/​S0140-6736(13)61950-9.CrossRefPubMed
35.
Zurück zum Zitat Kamrava M, Kuske RR, Anderson B, Chen P, Hayes J, Quiet C, et al. Outcomes of breast cancer patients treated with accelerated partial breast irradiation via multicatheter interstitial brachytherapy: the pooled registry of multicatheter interstitial sites (PROMIS) experience. Ann Surg Oncol. 2015;22:404–11. doi:10.1245/s10434-015-4563-7. CrossRef Kamrava M, Kuske RR, Anderson B, Chen P, Hayes J, Quiet C, et al. Outcomes of breast cancer patients treated with accelerated partial breast irradiation via multicatheter interstitial brachytherapy: the pooled registry of multicatheter interstitial sites (PROMIS) experience. Ann Surg Oncol. 2015;22:404–11. doi:10.​1245/​s10434-015-4563-7. CrossRef
36.
Zurück zum Zitat Chen PY, Shah C, Wilkinson JB, et al. Efficacy of young patients treated with accelerated partial breast irradiation for early-stage breast cancer. Radiother Oncol. 2012;103(Suppl 2):S36–7. doi:10.1016/S0167-8140(12)72057.CrossRef Chen PY, Shah C, Wilkinson JB, et al. Efficacy of young patients treated with accelerated partial breast irradiation for early-stage breast cancer. Radiother Oncol. 2012;103(Suppl 2):S36–7. doi:10.​1016/​S0167-8140(12)72057.CrossRef
Metadaten
Titel
Impact of young age on local control after partial breast irradiation in Japanese patients with early stage breast cancer
verfasst von
Kazuhiko Sato
Yoshio Mizuno
Hiromi Fuchikami
Masahiro Kato
Takahiro Shimo
Jun Kubota
Naoko Takeda
Yuko Inoue
Hiroshi Seto
Tomohiko Okawa
Publikationsdatum
01.02.2016
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 1/2017
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0669-4

Weitere Artikel der Ausgabe 1/2017

Breast Cancer 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.